MCID: THY023
MIFTS: 57

Thymoma malady

Categories: Cancer diseases, Immune diseases, Endocrine diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Thymoma

Aliases & Descriptions for Thymoma:

Name: Thymoma 12 52 42 14 69
Thymus Neoplasms 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3275
MeSH 42 D013945
NCIt 47 C3411
UMLS 69 C0040100

Summaries for Thymoma

Disease Ontology : 12 A thymus cancer that derives from epithelial cells located in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus.

MalaCards based summary : Thymoma, also known as thymus neoplasms, is related to combined thymoma and mixed type thymoma, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Thymoma is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are Developmental Biology and Response to elevated platelet cytosolic Ca2+. The drugs Prednisone and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include thymus, t cells and thyroid, and related phenotypes are Increased cell viability after pRB stimulation and normal

Wikipedia : 71 A thymoma is a tumor originating from the epithelial cells of the thymus that may be benign or... more...

Related Diseases for Thymoma

Diseases in the Thymoma family:

Thymoma, Familial Invasive Malignant Thymoma
Type C Thymoma Malignant Type Ab Thymoma
Malignant Type a Thymoma Thymoma Type a
Thymoma Type B Thymoma Type Ab

Diseases related to Thymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
id Related Disease Score Top Affiliating Genes
1 combined thymoma 32.5 AKT3 CD5 DNTT DPYSL5 NKX2-1
2 mixed type thymoma 29.6 AIRE AKT1 AKT2 AKT3 CD2 CD5
3 immunodeficiency with thymoma 12.1
4 thymoma, familial 12.0
5 spindle cell thymoma 11.9
6 invasive malignant thymoma 11.9
7 cortical thymoma 11.9
8 type c thymoma 11.9
9 encapsulated thymoma 11.9
10 predominantly cortical thymoma 11.8
11 epithelial malignant thymoma 11.8
12 dendritic cell thymoma 11.8
13 malignant type ab thymoma 11.7
14 noninvasive malignant thymoma 11.7
15 malignant type a thymoma 11.7
16 thymoma type a 11.7
17 thymoma type b 11.7
18 thymoma type ab 11.7
19 good syndrome 11.7
20 thymoma, childhood 11.6
21 myasthenia gravis 11.3
22 pure red-cell aplasia 11.2
23 acquired pure red cell aplasia 11.1
24 thymus cancer 11.0
25 thymic epithelial tumor 11.0
26 teratocarcinoma 10.2 CD5 LCK TTN
27 freemartinism 10.2 CD2 PTPRC
28 ovarian clear cell malignant adenofibroma 10.1 CD2 CD5 PTPRC TTN
29 cervicitis 10.1
30 mediastinitis 10.1
31 pemphigus 10.1
32 theileriasis 10.1 CD5 IL2 PTPRC
33 encephalitis 10.0
34 spinal cord intramedullary teratoma 10.0 CD5 DNTT PTPRC
35 lymphoma 10.0
36 malignant pleural solitary fibrous tumor 10.0 AKT1 AKT3 IL2 NKX2-1
37 myocarditis 10.0
38 thyroiditis 9.9
39 cd3epsilon deficiency 9.9 CD5 LCK PTPRC THY1
40 candidiasis 9.9
41 limbic encephalitis 9.9
42 neonatal stroke 9.9 IL2 RYR1 TTN
43 stiff-person syndrome 9.9
44 leukemia 9.9
45 myositis 9.9
46 lichen planus 9.9
47 superior vena cava syndrome 9.9
48 thymic hyperplasia 9.9
49 paraneoplastic pemphigus 9.9
50 chronic mucocutaneous candidiasis 9.8

Graphical network of the top 20 diseases related to Thymoma:



Diseases related to Thymoma

Symptoms & Phenotypes for Thymoma

Human phenotypes related to Thymoma:

32 (show all 29)
id Description HPO Frequency HPO Source Accession
1 fatigue 32 HP:0012378
2 dyspnea 32 HP:0002094
3 chest pain 32 HP:0100749
4 ptosis 32 HP:0000508
5 diplopia 32 HP:0000651
6 dysphagia 32 HP:0002015
7 arthritis 32 HP:0001369
8 pancytopenia 32 HP:0001876
9 hemolytic anemia 32 HP:0001878
10 limitation of joint mobility 32 HP:0001376
11 abnormality of the pleura 32 HP:0002103
12 thyroiditis 32 HP:0100646
13 decreased antibody level in blood 32 HP:0004313
14 nephrotic syndrome 32 HP:0000100
15 keratoconjunctivitis sicca 32 HP:0001097
16 xerostomia 32 HP:0000217
17 pericarditis 32 HP:0001701
18 myocarditis 32 HP:0012819
19 skin rash 32 HP:0000988
20 alopecia 32 HP:0001596
21 cough 32 HP:0012735
22 lymphadenopathy 32 HP:0002716
23 myositis 32 HP:0100614
24 b lymphocytopenia 32 HP:0010976
25 fatigable weakness 32 HP:0003473
26 abnormality of the peritoneum 32 HP:0002585
27 neoplasm of the thymus 32 HP:0100521
28 abnormality of the mediastinum 32 HP:0045026
29 interstitial pulmonary abnormality 32 HP:0006530

GenomeRNAi Phenotypes related to Thymoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AKT1 AKT2 AKT3 LCK

MGI Mouse Phenotypes related to Thymoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.73 DNTT NKX2-1 PPL PTPRC THY1 TTN
2 neoplasm MP:0002006 9.7 AIRE AKT1 AKT2 AKT3 IL2 NKX2-1
3 respiratory system MP:0005388 9.23 AIRE AKT1 AKT2 IL2 NKX2-1 PTPRC

Drugs & Therapeutics for Thymoma

Drugs for Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
2
Azathioprine Approved Phase 4 446-86-6 2265
3 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
6 Antirheumatic Agents Phase 4,Phase 2,Phase 1
7 glucocorticoids Phase 4,Phase 3,Phase 2
8 Hormone Antagonists Phase 4,Phase 3,Phase 2
9 Hormones Phase 4,Phase 3,Phase 2
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Antimetabolites Phase 4
12 Antimetabolites, Antineoplastic Phase 4
13
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
17
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
18 Liver Extracts Phase 3,Phase 1,Phase 2
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
20 Etoposide phosphate Phase 3,Phase 2,Phase 1
21 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
22 Adjuvants, Anesthesia Phase 3
23 Analgesics Phase 3,Phase 1,Phase 2
24 Analgesics, Opioid Phase 3
25 Anesthetics Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Central Nervous System Depressants Phase 3
29 Narcotics Phase 3
30 pancreatic polypeptide Phase 3
31 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
32 Methylprednisolone acetate Phase 3,Phase 2
33 Methylprednisolone Hemisuccinate Phase 3,Phase 2
34 Prednisolone acetate Phase 3,Phase 2
35 Prednisolone hemisuccinate Phase 3,Phase 2
36 Prednisolone phosphate Phase 3,Phase 2
37 Cola Nutraceutical Phase 3,Phase 2,Phase 1
38
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
39
Melphalan Approved Phase 2 148-82-3 4053 460612
40
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
41
Bevacizumab Approved, Investigational Phase 2 216974-75-3
42
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
43
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
44
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
45
Busulfan Approved, Investigational Phase 2 55-98-1 2478
46
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
47
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
48
Somatostatin Approved Phase 2 38916-34-6, 51110-01-1 53481605
49
Cyclosporine Approved, Investigational, Vet_approved Phase 2 79217-60-0, 59865-13-3 5284373 6435893
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 83)
id Name Status NCT ID Phase
1 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Active, not recruiting NCT00987116 Phase 4
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3
4 Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
5 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3
6 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2
7 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2
8 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2
9 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2
10 Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma Completed NCT00332969 Phase 2
11 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2
12 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2
13 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2
14 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2
15 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
16 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2
17 Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01369849 Phase 1, Phase 2
18 High Dose Somatostatin Analogues in Neuroendocrine Tumors Completed NCT00990535 Phase 2
19 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2
20 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2
21 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity Completed NCT01163552 Phase 2
22 A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Recruiting NCT02220855 Phase 2
23 Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma Recruiting NCT02636556 Phase 2
24 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2
25 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2
26 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Recruiting NCT02629419 Phase 2
27 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
28 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting NCT01306045 Phase 2
29 Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies Recruiting NCT03094832 Phase 1, Phase 2
30 Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Active, not recruiting NCT01301391 Phase 2
31 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2
32 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2
33 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2
34 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2
35 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Active, not recruiting NCT01011439 Phase 2
36 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting NCT01802320 Phase 2
37 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Active, not recruiting NCT01964924 Phase 2
38 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Active, not recruiting NCT02623127 Phase 2
39 MK-3475 in Patients With Thymic Carcinoma Active, not recruiting NCT02364076 Phase 2
40 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Not yet recruiting NCT03134118 Phase 2
41 K-BASKET, TAS-117, PI3K/AKT Gene Aberration Not yet recruiting NCT03017521 Phase 2
42 Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Not yet recruiting NCT02859415 Phase 1, Phase 2
43 A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Not yet recruiting NCT02607631 Phase 2
44 Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Suspended NCT02054104 Phase 1, Phase 2
45 Paclitaxel and Cisplatin for Thymic Neoplasm Terminated NCT00818090 Phase 2
46 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2
47 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Terminated NCT01100944 Phase 1, Phase 2
48 18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma Withdrawn NCT01610544 Phase 2
49 Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Unknown status NCT01242072 Phase 1
50 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1

Search NIH Clinical Center for Thymoma

Cochrane evidence based reviews: thymoma

Genetic Tests for Thymoma

Anatomical Context for Thymoma

MalaCards organs/tissues related to Thymoma:

39
Thymus, T Cells, Thyroid, Lung, Skin, B Cells, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Thymoma:

18
The Thymus

Publications for Thymoma

Articles related to Thymoma:

(show top 50) (show all 1036)
id Title Authors Year
1
Role of Postoperative Radiation Therapy inA Completely Resected Thymoma. ( 28007247 )
2017
2
Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit inA the Setting of the FutureA Adoption of the IASLC-ITMIG TNM-Based Staging System. ( 27988104 )
2017
3
Thymoma-associated multi-organ autoimmunity: two cases and a review of the literature. ( 28052464 )
2017
4
Thymoma-associated immunodeficiency: a diagnostic challenge for the clinician. ( 28068785 )
2017
5
GVHD-like erythroderma in the clinical course of thymoma-associated myasthenia gravis. ( 28524043 )
2017
6
Robotic thymectomy for myasthenia gravis with or without thymoma-surgical and neurological outcomes. ( 28084239 )
2017
7
Nephrotic syndrome associated with metastatic thymoma treated with chemotherapy. ( 28072685 )
2017
8
miR-20b Inhibits T Cell Proliferation and Activation via NFAT Signaling Pathway in Thymoma-Associated Myasthenia Gravis. ( 27833920 )
2016
9
Thymoma Complicated by Situs Inversus Totalis. ( 26831245 )
2016
10
Gene-Specific Methylation Analysis in Thymomas of Patients with Myasthenia Gravis. ( 27999265 )
2016
11
Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab. ( 27408396 )
2016
12
Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma. ( 27076925 )
2016
13
Enlargement of thymoma triggers overlapping autoimmune diseases. ( 27129431 )
2016
14
Autoimmune hepatitis: an uncommon presentation of thymoma. ( 27079907 )
2016
15
IL-6-specific autoantibodies among APECED and thymoma patients. ( 27957331 )
2016
16
Atypical Location of a Thymoma. ( 27562328 )
2016
17
Preoperative misdiagnosis analysis and accurate distinguish intrathymic cyst from small thymoma on computed tomography. ( 27621863 )
2016
18
Spontaneous rupture of hepatic metastasis from a thymoma: A case report. ( 27956811 )
2016
19
Cerebral toxoplasmosis in a patient with myasthenia gravis and thymoma with immunodeficiency/Good's syndrome: a case report. ( 27576953 )
2016
20
A case of anterior mediastinitis and bilateral multiple lung abscesses occurring after trans-subxiphoid video-assisted thoracoscopic extended thymectomy for thymoma with myasthenia gravis. ( 27747038 )
2016
21
Thoracoscopic resection of bulky thymoma assisted with artificial pneumothorax: A report of 19 consecutive cases. ( 27123063 )
2016
22
Ectopic Hamartomatous Thymoma-New Insights Into a Challenging Entity: A Clinicopathologic and Immunohistochemical Study of 9 Cases. ( 27428736 )
2016
23
Considerations about the ability of computed tomography to predict the clinical stage of thymoma. ( 27044901 )
2016
24
Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma. ( 27387303 )
2016
25
Coincidence of thymoma and breast cancer and in a 56-year-old female patient. ( 27999780 )
2016
26
Response to Pembrolizumab in a Patient with Relapsing Thymoma. ( 27498287 )
2016
27
Thymoma with an incidental benign laryngeal mass mimicking laryngeal carcinoma: Case report. ( 26930331 )
2016
28
Case of thymoma-associated multi-organ autoimmunity following herpes zoster. ( 27943470 )
2016
29
The clinical features, diagnosis and management of recurrent thymoma. ( 27580949 )
2016
30
Thoracoscopic thymectomy versus open thymectomy for the treatment of thymoma: A meta-analysis. ( 27139936 )
2016
31
Clinicopathologic and prognostic factors of thymoma in Tunisia. ( 27532527 )
2016
32
Invasive Thymoma with Pure Red Cell Aplasia and Amegakaryocytic Thrombocytopenia. ( 28053696 )
2016
33
Ectopic micronodular thymoma with lymphoid stroma in the cervical region: a rare case associated with Langerhans cells proliferation. ( 27486334 )
2016
34
Journal of Thoracic Disease Focused Issue: Management of Thymoma. ( 27114829 )
2016
35
Thymoma in middle mediastinum that induced tracheal compression-Case report and literature review. ( 28024212 )
2016
36
214P: Correlation of thymoma with myasthenia gravis in ten years experience of their surgical treatment. ( 27198348 )
2016
37
Histiocytic necrotising lymphadenitis in mediastinum mimicking thymoma or lymphoma - case presentation and literature review of Kikuchi Fujimoto disease. ( 27179280 )
2016
38
Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective. ( 27497628 )
2016
39
Massive thymoma of the mid-posterior mediastinum: an unprecedented case in a young adult. ( 28057967 )
2016
40
Ectopic pleural thymoma in a 49-year-old woman: A case report. ( 27633912 )
2016
41
Frequency of Synaptic Autoantibody Accompaniments and Neurological Manifestations of Thymoma. ( 27135398 )
2016
42
"Cryptic" mediastinal tuberculosis with myasthenia-thymoma complex. ( 27451826 )
2016
43
Postoperative survival for patients with thymoma complicating myasthenia gravis-preliminary retrospective results of the ChART database. ( 27114839 )
2016
44
Thymoma-associated cutaneous graft-versus-host-like disease possibly treated with Narrow-band UVB phototherapy. ( 27018042 )
2016
45
Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity. ( 28026038 )
2016
46
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma. ( 27076933 )
2016
47
Impact of Surgical Evaluation of Additional Cine Magnetic Resonance Imaging for Advanced Thymoma with Infiltration of Adjacent Structures: The Thoracic Surgeon's View. ( 27177265 )
2016
48
Concurrent spindle-cell thymoma and thymic cysts in a Barbary sheep (Ammotragus lervia): case report and review of the literature. ( 27698165 )
2016
49
V-akt murine thymoma viral oncogene homolog 3 (AKT3) contributes to poor disease outcome in humans and mice with pneumococcal meningitis. ( 27193124 )
2016
50
[The role of TNIP1 in the pathogenesis of myasthenia gravis among patients with thymoma]. ( 27577206 )
2016

Variations for Thymoma

ClinVar genetic disease variations for Thymoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
2 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
3 KIT NM_000222.2(KIT): c.1657T> A (p.Tyr553Asn) single nucleotide variant Pathogenic rs1057519704 GRCh37 Chromosome 4, 55593591: 55593591
4 KIT NM_000222.2(KIT): c.2460T> A (p.Asp820Glu) single nucleotide variant Pathogenic rs1057519711 GRCh37 Chromosome 4, 55599334: 55599334
5 KIT NM_000222.2(KIT): c.1468G> A (p.Glu490Lys) single nucleotide variant Pathogenic rs1057519701 GRCh37 Chromosome 4, 55592144: 55592144
6 KIT NM_000222.2(KIT): c.1669T> C (p.Trp557Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913235 GRCh38 Chromosome 4, 54727437: 54727437
7 KIT NC_000004.11: g.55593612_55593612delGTT single nucleotide variant Pathogenic GRCh37 Chromosome 4, 55593612: 55593612
8 KIT NM_000222.2(KIT): c.1727T> C (p.Leu576Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913513 GRCh37 Chromosome 4, 55593661: 55593661
9 KIT NC_000004.11: g.55593664_55593664delCTTATGATC single nucleotide variant Pathogenic GRCh37 Chromosome 4, 55593664: 55593664

Expression for Thymoma

Search GEO for disease gene expression data for Thymoma.

Pathways for Thymoma

Pathways related to Thymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 AKT1 AKT2 AKT3 DPYSL5 EVPL IL2
2
Show member pathways
13.26 AKT1 AKT2 AKT3 CD2 IL2 LCK
3
Show member pathways
12.53 AKT1 AKT2 AKT3 LCK PTPRC
4
Show member pathways
12.53 AKT1 AKT2 AKT3 IL2 LCK PTPRC
5
Show member pathways
12.44 AKT1 AKT2 AKT3 IL2
6
Show member pathways
12.37 AKT1 AKT2 AKT3 RYR1
7 12.36 AKT1 AKT2 AKT3 IL2 LCK
8
Show member pathways
12.31 AKT1 AKT2 AKT3 LCK PTPRC
9 12.28 AKT1 AKT2 AKT3 PTMA
10
Show member pathways
12.24 AKT1 AKT2 AKT3 LCK PTPRC
11
Show member pathways
12.21 AKT1 AKT2 AKT3 IL2 LCK PTPRC
12
Show member pathways
12.19 AKT1 AKT2 AKT3 LCK
13
Show member pathways
12.19 AKT1 AKT2 AKT3 IL2
14 12.05 AKT1 AKT2 AKT3 RYR1
15
Show member pathways
12.01 AKT1 AKT2 AKT3 IL2 LCK PTPRC
16 12 AKT1 AKT2 AKT3 LCK
17
Show member pathways
11.98 AKT1 AKT2 AKT3 IL2
18
Show member pathways
11.95 AKT1 AKT2 AKT3 IL2 LCK
19
Show member pathways
11.95 AKT1 AKT2 AKT3 IL2 LCK
20 11.92 AKT1 AKT2 AKT3
21
Show member pathways
11.9 AKT1 AKT2 AKT3
22 11.9 AKT1 AKT2 AKT3
23 11.9 AKT1 AKT2 AKT3
24 11.89 AKT1 AKT2 AKT3
25 11.88 CD2 CD5 DNTT
26 11.85 AKT1 AKT2 AKT3
27 11.83 AKT1 AKT2 AKT3
28
Show member pathways
11.82 AKT1 AKT2 AKT3
29 11.82 AKT1 AKT2 AKT3
30 11.81 AKT1 AKT2 AKT3
31
Show member pathways
11.8 AKT1 AKT2 AKT3
32 11.78 IL2 PTPRC THY1
33 11.78 AKT1 AKT2 AKT3 PTPRC
34 11.75 AKT1 LCK PTPRC
35 11.75 IL2 PTPRC THY1
36 11.73 AKT1 AKT2 AKT3
37
Show member pathways
11.72 AKT1 AKT2 AKT3
38 11.72 CD2 CD5 IL2 PTPRC THY1
39 11.7 AKT1 AKT2 AKT3
40
Show member pathways
11.7 AKT1 AKT2 AKT3 IL2
41
Show member pathways
11.68 AKT1 IL2 LCK
42 11.66 AKT1 AKT2 AKT3
43 11.63 AKT1 AKT2 AKT3 LCK
44 11.62 AKT1 AKT2 AKT3
45 11.59 AKT1 AKT2 AKT3 LCK
46
Show member pathways
11.57 AKT1 AKT2 AKT3
47 11.57 AKT1 AKT2 AKT3
48 11.57 AKT1 AKT2 AKT3
49 11.55 CD5 PTPRC THY1
50 11.53 AKT1 AKT2 AKT3

GO Terms for Thymoma

Cellular components related to Thymoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD2 CD5 PTPRC THY1

Biological processes related to Thymoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 T cell costimulation GO:0031295 9.58 AKT1 CD5 LCK
2 positive regulation of glycogen biosynthetic process GO:0045725 9.46 AKT1 AKT2
3 mammary gland epithelial cell differentiation GO:0060644 9.43 AKT1 AKT2
4 positive regulation of glucose metabolic process GO:0010907 9.37 AKT1 AKT2
5 release of sequestered calcium ion into cytosol GO:0051209 9.33 LCK PTPRC RYR1
6 peripheral nervous system myelin maintenance GO:0032287 9.32 AKT1 AKT2
7 negative regulation of plasma membrane long-chain fatty acid transport GO:0010748 9.26 AKT1 AKT2
8 T cell differentiation GO:0030217 9.13 IL2 LCK PTPRC
9 regulation of cell migration GO:0030334 8.92 AKT1 AKT2 THY1 TMSB4X

Molecular functions related to Thymoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.65 AKT1 AKT2 AKT3 LCK TTN
2 protein kinase binding GO:0019901 9.35 AKT1 LCK PTPRC THY1 TTN
3 enzyme binding GO:0019899 9.1 AKT1 NKX2-1 RYR1 THY1 TMSB4X TTN
4 protein binding GO:0005515 10.09 AIRE AKT1 AKT2 AKT3 CD2 CD5

Sources for Thymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....